UPDATE: August 12, 2020. – The USTA’s Harness Racing Medication Collaborative has formally re-submitted three proposed Model Rule modifications dealing with Clenbuterol, Betamethasome, and Methylprednisolone policy in standardbred racing only. The ARCI Scientific Advisory Group will meet to consider this matter on August 28, 2020.
The ARCI Scientific Advisory Group has previously assessed clenbuterol and reported to the Drug Testing Standards and Practices Committee in April, 2019 that different policies might be appropriate for different types of racing to ensure equine health without compromising the integrity of the contests. At that time they opened the door to a 96-hour withdrawal time for clenbuterol but did not suggest or recommend adoption of the USTA proposed threshold, pending further review and information. The same was true for Betamethasome.
USTA Letter to Commissions with Proposal: 2018 12 03 USTA Medication Letter to Commissions
ARCI Letter to Commissions: 2018 12 10 ARCI LETTER TO COMMISSIONS
USTA Response to ARCI Letter: 2018 12 18 MedCollaborative Response to RCI Letter
RMTC Scientific Advisory Committee Comments on Proposals. 2019 02 13 – RMTC Comments on USTA Medication Proposal. List of Members of the RMTC SAC 2019 RMTC SAC Members
MATERIALS FOR REVIEW:
USTA JUSTIFICATION FOR BREED SPECIFIC POLICY DIFFERENCES FOR THERAPEUTIC MEDICATIONS.
2015 Finding of the NY Gaming Commission – 2019 02 21 NYSGC findings on clenbuterol